Adamas One Corp. Provides Shareholder Update
SCOTTSDALE, Ariz., Feb. 24, 2024 (GLOBE NEWSWIRE) — Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original […]
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
– Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose […]
